or years, the pharmaceutical industry has maintained that high prices charged for many medicines in the US are needed to fund R&D, since so many other countries use various means to cap pricing.

Now, though, a new analysis suggests that the additional sales that drug companies generate in the US, compared with four other well-to-do countries, greatly exceeds what they have spent on their global research and development.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I have a different take. One way to interpret the data is that in the US the drug companies had to actually spend one dollar in R&D to squeeze out an additional 63 cents in revenue, basically the R&D was 63% of the additional sales. Considering that the overall average R&D spend is about 15% of sales what we see here is a perfect example of the Law of Diminishing Returns. Historically we in pharma we have enjoyed as an ROI of 7-10 X R&D costs. Those days are gone, not because of declining revenues but because drug shops have been forced to ramp up R&D spend (which does indeed flow through to higher prices) in order to go after the more elusive diseases.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.